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Abstract
Background: A frequent manifestation of advanced NSCLC is malnutrition, even though there are many studies
which relate it with a poor survival, its relation with toxicity has not yet been consistently reported. The aim of this
study was to associate malnutrition and albumin serum levels with the occurrence of chemotherapy-induced
toxicity in cisplatin plus paclitaxel chemotherapy-treated NSCLC.
Methods: We prospectively evaluated 100 stage IV NSCLC patients treated with paclitaxel (175 mg/m
2) and
cisplatin (80 mg/m
2). Malnutrition was assessed using SGA prior treatment. Neutrophil Lymphocyte Ratio (NLR) and
the Platelet Lymphocyte Ratio (PLR) were used to determine the presence of systemic inflammatory response (SIR)
and were related to the development of toxicity. Toxicity was graded according to NCI CTCAE version 3.0 after two
chemotherapy cycles.
Results: Median age was 58 ± 10 years, 51% of patients were malnourished, 50% had albumin ≤3.0 mg/mL. NLR ≥
5 was associated with basal hypoalbuminemia (mean ranks, 55.7 vs. 39 p = 0.006), ECOG = 2 (47.2 vs. 55.4 p =
0.026) and PLR ≥ 150 were significantly related with a basal body mass index ≤20 (56.6 vs. 43.5; p = 0.02) and
hypoalbuminemia (58.9 vs. 41.3; p = 0.02). Main toxicities observed after 2 cycles of chemotherapy were alopecia
(84%), nausea (49%), neuropathy (46%), anemia (33%), lymphopenia (31%), and leukopenia (30%). Patients
malnourished and with hypoalbuminemia developed more chemotherapy-induced toxicity overall when compared
with those without malnutrition (31 vs 22; p = 0.02) and normal albumin (mean ranks, 62 vs 43; p = 0.002),
respectively. Hypoalbuminemia was associated with anemia (56 vs 47; p = 0.05), fatigue (58 vs 46; p = 0.01), and
appetite loss (57.1 vs 46.7; p = 0.004) compared with normal albumin. PLR ≥ 150 was related with the
development of toxicity grade III/IV (59.27 vs. 47.03 p = 0.008) and anemia (37.9 vs 53.8 p = 0.004).
Conclusion: SIR parameters were associated with malnutrition, weight loss and hypoalbuminemia. Chemotherapy-
induced toxicity in NSCLC patients treated with paclitaxel and cisplatin was associated with malnutrition and
hypoalbuminemia. Early nutritional assessment and support might confer beneficial effects.
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Non-small-cell lung cancer (NSCLC) is highly prevalent
and the major cause of cancer-related deaths in the U.
S., Mexico, and worldwide [1-3]. NSCLC represents
approximately 80% of lung neoplasms. While surgery is
the principal curative option, fewer than 20% of patients
have resectable disease, permitting their being operated
at time of diagnosis [4]. Multiple studies have clearly
shown that chemotherapy is important in the palliative
care of advanced NSCLC, with objective tumor-response
percentages of 25-35%; significant extension of overall
survival has also been obtained when compared with the
best support treatment. One of the most frequently
employed first-line regimens consists of cisplatin (P)
plus paclitaxel (TXN) [5].
P is widely used as part of the treatment of various
malignant neoplasms, such as ovary, breast, lung, and
head and neck cancer [6,7]. Further improvements in
survival have been achieved when it is combined with
third-generation agents [8,9]. TXN has the ability to
block cells in the late G2 phase of the cell cycle by
microtubule polymerization and stabilization [10]. TXN
is transported by binding with plasma proteins, such as
albumin, the latter significant for its pharmacokinetic
behavior; it is also extensively protein-bound (95-98%)
to tissue proteins [11], and its removal is primarily car-
ried out by hepatic metabolism [12].
Despite efforts to diminish treatment-related toxicity
and to preserve or improve patients’ quality of life
(QOL), all combinations of platin and third-generation
agents including their modifications maintain a percen-
tage of adverse events [13]. The most common hemato-
logic adverse effects comprise leukopenia and anemia,
while the most frequently found non-hematologic
adverse reactions are nausea and vomiting. Peripheral
neuropathy, arthralgias, myalgias, and dermatologic toxi-
city can be encountered less frequently, rendering dose
reduction necessary [14-16].
The prevalence of malnutrition-associated morbidity in
patients with cancer ranges from 40-80% [17]. The pro-
cess of nutritional and functional decline in the patient
with cancer is so common that it is often accepted as
part of the disease itself and its treatment. Currently,
there is evidence that the presence of a systemic inflam-
matory response (SIR) is associated with increased weight
loss, an elevated resting energy expenditure, loss of lean
tissue and functional decline [18]. Malnutrition is asso-
ciated with a higher risk of developing complications and
with mortality, sometimes lengthening the hospital stay
by up to 90%, thus increasing hospitalization costs by
35-75% [19]; malnutrition is also related with a reduction
in response [20,21], hence influencing QOL of patients,
their sense of well-being, and emotional aspects.
Malnutrition is related with hypoalbuminemia, and both
are common in patients with NSCLC [22], especially in
non-developed countries, where malnutrition is prevalent
in itself. Currently, there are certain clinical and biochem-
ical measurements utilized in the nutritional evaluation of
oncologic patients, such as the Subjective Global Assess-
ment (SGA) [23], as well as the albumin serum levels,
which reflects both the loss of the amount of lean tissue
and systemic inflammatory response [18,24-26]. Neutro-
phil Lymphocyte Ratio (NLR) and the Platelet Lympho-
cyte Ratio (PLR) have also been demonstrated as
indicators of systemic inflammatory response [18].
Indeed, the magnitude of the increase PLR and NLR has
been shown to be associated with poorer survival in
patients with cancer, particularly in patients with
advanced disease [27-30]. The aim of this study was to
associate malnutrition and albumin serum levels with the
occurrence of chemotherapy-induced toxicity in P plus
TXN treated NSCLC.
Methods
Study population
With previous institutional research and ethics board
approval, we conducted a prospective analytical study at
the Instituto Nacional de Cancerología in Mexico City.
All patients gave written informed consent. We evalu-
ated 100 consecutive patients recently diagnosed with
NSCLC who attended the Thorax Neoplasms Clinic
from January 2007 to February 2009. Inclusion criteria
were as follows: patients with a diagnosis of stage IV
histopathological or cytological NSCLC, with Eastern
Cooperative Oncology Group (ECOG) score of ≤2, aged
18-80 years, and eligibility to receive TXN (175 mg/m
2)
and P (80 mg/m
2) based first-line palliative chemother-
apy every 3 weeks for at least two cycles. Exclusion cri-
teria included patients who declined participation in the
study, who required biochemical or hematological
alteration-related P or TXN dose reduction, who had
poor functional state, those who had received previous
treatment (surgical, radiotherapy, and/or chemotherapy),
and patients with signs of infection, acute inflammatory
processes, or liver disorders.
Procedures
Prior to chemotherapy administration, clinical, biochem-
ical, and nutritional evaluations by means of Subjective
Global Assessment (SGA) were conducted. Initial values
were collected in a database that also included patient
characteristics. All patients received chemotherapy at the
institution with the same premedication drugs (aprepitant
day 1: 125 mg; 2
nd and 3
rd days, 80 mg PO, ondansetron
16 mg IV, dexamethasone 16 mg IV, chlorphenamine 10
mg IV, ranitidine hydrochloride 50 mg IV) and hydration.
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Page 2 of 7The biochemical evaluation comprised complete blood
count (including lymphocytes), blood chemistry (glu-
cose, BUN, and creatinine), and liver function tests
(AST, ALT, total and direct bilirubin, total proteins,
albumin, and globulin). Venous blood samples were
drawn from patients after an overnight fast. All labora-
tory values were determined using routine automated
analyzers at the Department of Clinical Chemistry of
the Instituto Nacional de Cancerología. Serum albumin
levels were measured with the bromcresol purple
method and employed as the biochemical marker of
nutritional status: levels <3.5 mg/dL of albumin (hypoal-
buminemia) were taken to indicate malnutrition; in
addition, levels <3.8 mg/dL were considered for analysis,
given that this is the lower limit used at the Institute.
The NLR was defined as the absolute neutrophil count
divided by the absolute lymphocyte count. The PLR was
defined as the absolute platelet count divided by the
absolute lymphocyte count. Both the NLR and PLR
were calculated from the full blood count routinely per-
formed one day before the first cycle of chemotherapy:
NLR ≥5a n dP L R≥150 were taken to indicate SIR as
previously described [18,27-30].
Baseline nutritional status evaluation was performed
by three Clinical Nutritionists (CNs) (KS, GS, and ST)
and consisted of questionnaires utilized for detection of
undernourishment, anorexia, hunger-satiety sensations,
a n dS G A ;t h eC N sw e r eb l i n d e dt ot h et o x i c i t ye v a l u a -
tion. SGA consists of a brief nutritional history (weight
loss during the last 6 months, dietary changes, and a
short physical examination of subcutaneous fat, muscle
mass, albumin serum levels and fluid balance). SGA
classifies patients as having severe or moderate mal-
nourishment, or being well-nourished.
The clinical evaluation included ECOG, weight, height,
and body mass index (BMI). Body weight was measured,
in light clothing and without shoes, to the nearest 0.10
kg. Height was measured to the nearest 0.5 cm. BMI
was calculated as weight (kg)/height squared (m
2). BMI
<20 is widely accepted as indicating that the subject is
underweight, particularly in well-developed countries,
and 18.5 is recommended as a practical lower limit for
the majority of populations. Therefore, a diagnosis of
malnutrition was made when BMI was <18.5 kg/m
2.
After two chemotherapy cycles were received, bio-
chemical evaluation was repeated and signs and symp-
toms of toxicity were evaluated; these were graded
according to National Cancer Institute Common Termi-
nology Criteria of Adverse Events (NCI CTCAE) (ver-
sion 3.0).
Statistical analysis
For descriptive purposes, continuous variables were
summarized as arithmetic means, medians, and standard
deviations (SDs), while categorical variables were
expressed as proportions and confidence intervals (CIs).
Inferential comparisons between groups (changes in bio-
chemical values) were carried out using the Student t or
the Mann-Whitney U test, according to data distribution
determined by the Kolmogorov-Smirnov test. The chi
squared or Mann-Whitney U test were utilized to
associate clinical and biochemical parameters, and
malnutrition. Statistical significance was determined as
p < 0.05 with a two-sided test. SPSS software package
version 15 (SPSS, Inc., Chicago, IL, USA) was employed
to analyze the data.
Results
General characteristics of all patients are shown in
Table 1. Median age was 58.9 ± 10.5 years and mean
BMI was 24.9 ± 3.7 kg/m
2. Forty nine patients were
well-nourished at the time of SGA application (A) and
malnourishment was found in the remaining 51%: 34%
of patients were moderately malnourished (B) and 17%
were severely malnourished (C). The range of albumin
serum levels found in our patients was 2.5-4.3 mg/dL,
with a mean of 3.1 ± 0.5 mg/dL, which is below the
standard level of 3.5 mg/dL. The median NLR and PLR
were 3.5 and 225.7, respectively. NLR ≥ 5 was associated
Table 1 Clinical characteristics of the patients
Variable n = 100
Gender
Male 53%
Female 47%
Age years (mean ± sd) 58.9 ± 10.6
ECOG
08 %
1 65%
2 27%
BMI (kg/m
2)
Mean ± sd 24.9 ± 3.7
Median (range) 24.5 (15.9-35)
SGA
A 49%
B 34%
C 17%
Albumin (mg/dL)
Mean ± sd 3.1 ± 0.5
Diabetes at diagnosis 18%
NLR
Median (range) 3.5 (.32-34.3)
PLR
Median (range) 225.7 (16.2-843.3)
ECOG = Eastern Cooperative Oncology Group; BMI = Body Mass
Index; SGA = Subjective Global Assessment; NLR = Neutrophil Lymphocyte
Ratio; PLR = Platelet Lymphocyte Ratio
Arrieta et al. BMC Cancer 2010, 10:50
http://www.biomedcentral.com/1471-2407/10/50
Page 3 of 7with baseline hypoalbuminemia (55.7 vs. 39 p = 0.006),
ECOG = 2 (47.2 vs. 55.4 p = 0.026). PLR ≥ 150 was sig-
nificantly related with a basal BMI ≤20 (56.6 vs. 43.5; p
= 0.02) and hypoalbuminemia (58.9 vs. 41.3; p = 0.02).
The main observed any grade non-hematologic toxici-
ties were alopecia (84%), nausea (49%) neuropathy
(46%), weight loss (44%) and vomiting (40%). The most
commonly observed any grade hematologic toxicities
were anemia, lymphopenia, and leukopenia in 33, 31,
and 30% of patients, respectively. No significant differ-
ences were found when relating toxicity and age. Male
patients developed anemia (38 vs. 61.5; p = 0.001) and
neuropathy (44 vs. 55; p = 0.03) more frequently than
female patients did. Patients with poor functional status
(ECOG 2) presented anemia (32.6 vs. 21.6; p =0 . 0 0 1 )
more frequently than those with a good functional
status (ECOG 0 and 1).
Patients who were moderately or severely malnour-
ished and with hypoalbuminemia developed more che-
motherapy-induced toxicity overall when compared with
patients without malnutrition (31 vs. 22; p = 0.02) and
normal albumin (54 vs. 41; p = 0.04), respectively.
Hypoalbuminemia was associated with anemia (56 vs.
47; p = 0.05), fatigue (58 vs. 46; p = 0.01), and appetite
loss (57.1 vs. 46.7; p = 0.004), in addition, it exhibited a
tendency for the occurrence of nausea and neuropathy.
Patients with diabetes showed a tendency to develop
neuropathy (p = 0.08). PLR ≥ 150 was significantly
related with the development of toxicity grade III/IV
(59.3 vs. 47 p = 0.008). Other clinical and nutritional
factors related with chemotherapy-induced toxicity are
shown in Table 2. Overall toxicity development was sig-
nificantly related with low albumin serum levels being
more significant as the levels decreased (Table 3).
Discussion
Nutritional and functional deterioration are so fre-
quently encountered in cancer patients that they are
often accepted as part of the disease and its treatment
[18]. The majority of patients with advanced NSCLC
also present with malnourishment [31-34] and subse-
quently, with hypoalbuminemia. In our study, we
found that one half of our patients were malnourished
and presented hypoalbuminemia prior to chemother-
apy. One of the most frequently employed first-line
t r e a t m e n t sf o rN S C L Ci sPp l u sT X N[ 3 5 ] ,b o t hh a v e
been strongly associated with toxic side effects [36].
However, the potential benefits of this therapy in gen-
eral outweigh the possible risks. The most common
side effects of TXN used alone or in combination
with other chemotherapy medications and demon-
strated in some trials include anemia, leukopenia,
neutropenia, alopecia, nausea, vomiting, and diarrhea
[14-16].
Table 2 Clinical and nutritional factors related to chemotherapy-induced toxicity development
Anemia Neuropathy Appetite loss Nausea Lymphopenia Fatigue All toxicities Toxicity Grade III/IV
Gender
(Female vs male)
0.001
(38 vs 61.5)
0.03
(44 vs 55)
.851 0.09
(55 vs 46)
0.9 0.5 0.5 0.5
ECOG
(0,1 vs 2)
0.001
(32.6 vs 21.6)
0.7 0.022
(45 vs 63)
0.09 0.6 0.2 0.8 0.2
Diabetes 0.2 0.08
(51 vs 47)
0.1 0.5 0.3 0.6 0.2 0.8
Albumin
(>3.1 vs ≤3.0)
0.05
(47 vs 56)
0.06
(36 vs 64)
0.004
(46.7 vs 57.1)
0.07
(48 vs 54)
0.8 0.01
(46 vs 58)
0.002
(43 vs 62)
0.6
Weight loss
(>10% vs <9.9))
0.3 0.05
(23 vs 30)
0.4 0.7 0.039
(23.4 vs 30.9)
0.3 0.5 0.2
BMI
(≤19.9 vs >20)
0.006
(48 vs 76)
0.08
(49 vs 68)
0.4 0.8 0.2 0.2 1.0 0.6
SGA
(well nourished vs
malnourished)
0.1 0.7 0.7 0.2 0.7 0.3 0.028
( 31 vs 22)
0.6
NLR
(≥5v s≤5)
0.1 0.8 0.2 0.8 - 0.8 0.2 0.7
PLR
(≥150 vs ≤150)
0.004
(37.9 vs 53.8)
0.8 0.7 0.4 - 0.2 0.2 .008
(59.3 vs 47)
ECOG = Eastern Cooperative Oncology Group; BMI = Body Mass Index; SGA = Subjective Global Assessment; NLR = Neutrophil Lymphocyte Ratio; PLR = Platelet
Lymphocyte Ratio
Table 3 Global toxicity in relation to albumin serum
levels before chemotherapy was given.
Albumin level Mean ranks P
≤ 3.8 38.5 vs 53.3 0.046
≤ 3.5 41 vs 54 0.040
≤ 3.1 43.8 vs 62.2 0.002
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Page 4 of 7The binding of TXN to plasma proteins such as albu-
min is important for achieving its therapeutic target.
Albumin binds TXN and transports it in the blood-
stream, allowing its gradual liberation, thus decreasing
its toxic effects [37]. Therefore, we thought it would be
useful not only for determining nutritional status, but
also for predicting toxicity in patients with NSCLC
under chemotherapy, given that albumin levels are not
influenced solely by the oncologic process, but also by
the patients protein and caloric intake prior to and dur-
ing treatment. We found that patients who were well-
nourished and with normal albumin levels benefited in
terms of developing less toxicity after two cycles of
TXN-P chemotherapy, on comparison with patients who
were malnourished and had serum albumin levels below
3.0 mg/dL, mainly in the development of anemia, neuro-
pathy, and nausea. In addition, with more severe hypoal-
buminemia, major toxicities were found (Table 3). Serum
albumin concentration has been traditionally used as a
biochemical marker of nutritional status; it is one of the
easiest parameters to measure and that which best reflects
the state of visceral protein [38]. Although albumin is the
main protein synthesized in liver [39], its long half-life and
broad distribution in the body prevent nutritional changes
from being reflected rapidly in albumin serum concentra-
tion [40]. Several processes control plasma albumin con-
centration, including absoluter a t eo fa l b u m i ns y n t h e s i s
and fractional catabolic rate (FCR), among others. It has
been previously demonstrated that patients with advanced
cancer have an important energy expenditure caused by
increased tumor metabolism [41] and specifically in
patients with NSCLC, also by means of chronic airway
limitation [42] Therefore, serum albumin levels can be
modified by tumor activity via increased FCR, but also by
decreasing albumin synthesis, given that the majority of
the time, patients with NSCLC display decreased appetite
[43] and diminish their food intake [44].
Currently, some studies have associated SIR with a
poor prognosis in different solid tumors, particularly in
lung cancer [40,45] The development of SIR in oncolo-
gic patients is unclear, which might be related to a
tumor hypoxia-necrosis and local tissue damage causing
disturbances in the neuro-endocrine metabolism, inter-
leukine synthesis and acute phase protein production
[46]. Clinical evidence has also shown that the activation
of the SIR is one of the earliest and most important
contributory factors of cachexia, moreover these findings
help explain the failure of simple nutritional programs
to reverse weight loss adequately in patients with cancer
[34]. In our study, we used two frequently used para-
meters of measuring SIR, NLR and PLR [18,27-30].
Besides, albumin synthesis may diminish with SIR
found in patients with advanced NSCLC [18]. We found
a relationship between ≥5 NLR and baseline hypoalbu-
minemia and also of PLR ≥150 with baseline hypoalbu-
minemia and low BMI. Moreover, patients who had an
initial PLR ≥150 develop higher toxicity grade III/IV and
anemia. In previous studies, PLR and NLR confer an
independent prognostic value in oncologic patients; an
increase in absolute neutrophil and platelet count might
be implicated in the development of methastases [47]
and low lymphocyte levels could be related to a
decreased cell-mediated immunity against tumor tissue
[48]. However, these values have not been used as mar-
kers of chemotherapy toxicity. Thus the NLR and PLR
might be potential biomarkers to predict whether a
patient will develop toxicity in this regard because it is
almost universally available and adds no additional cost
to routine laboratory measurements. Clearly further vali-
dation work and a feasibility study are required before it
can be considered for clinical use.
Although malnutrition has been associated with
increased hospitalization, increased susceptibility
to infection, reduced QOL, and increased mortality
[49-51], nutritional status evaluation may not be
afforded sufficient attention in the field of chemother-
apy-induced toxicity in patients with NSCLC, who
themselves represent a considerable risk factor for com-
plications and co-morbidities. Albumin is habitually
included among parameters utilized for nutritional
assessment and has recently become more widespread
[52]. It has also been established that serum albumin
concentration was an independent prognostic variable
for survival in 90 patients with NSCLC [53]. Notwith-
standing this, to date few data are available in the litera-
ture concerning the prevalence and clinical significance
of hypoalbuminemia in oncologic patients and the man-
ner in which it affects their treatment.
Albumin levels, PLR and NLR were all related to the
development of chemotherapy-induced toxicity. We
therefore consider that the SIR, hypoalbuminemia and
malnutrition in unison contribute to its further
development.
Conclusions
SIR parameters were associated with malnutrition,
weight loss and hypoalbuminemia. Malnutrition and
hypoalbuminemia are associated with the development
of chemotherapy-induced toxicity in patients with
NSCLC treated with P and TXN. Therefore, early nutri-
tional assessment and detection of SIR markers might
allow identification of patients at higher risk of develop-
ing chemotherapy toxicity and the implementation of an
adequate nutritional support might be accompanied by
beneficial effects when treating patients with NSCLC; in
turn, this may permit completion of maximum
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more favorable toxicity profile.
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